D. Roychowdhury

Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer

C. Poole, J. Cook, T. Perren, 2004, International Journal of Gynecologic Cancer.

Incidence of thrombocytopenia with gemcitabine-based therapy and influence of dosing and schedule

D. Roychowdhury, L. Cirera, P. Peterson, 2001, Anti-cancer drugs.

First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study.

D. Doval, J. Jassem, G. von Minckwitz, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy

J. Baselga, G. Sledge, K. Blackwell, 2008 .

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

I. Bodrogi, P. Conte, L. Dogliotti, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

I. Bodrogi, P. Conte, H. von der Maase, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cancer.

S. Johnston, D. Slamon, L. Pandite, 2009 .